Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Commissioning Support Appraisal Service (CSAS)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Commissioning Support Appraisal Service (CSAS)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Commissioning Support Appraisal Service (CSAS)
01 July 2011
(138.12 Kb 40 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 30 June 2011